Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia

Genes and Immunity

Volumn 16, Issue 1, 2015, Pages 71-82

  Baragano Raneros A ^a   Martin Palanco V ^b   Fernandez, A F ^c   Rodriguez, R M ^a   Fraga, M F ^c   Lopez Larrea, C ^a,d   Suarez Alvarez, B ^e  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^d Section of Nephrology   (Spain)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA DEOXYCYTIDINE; AZACITIDINE; DEOXYCYTIDINE; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HLA ANTIGEN CLASS 1; KLRK1 PROTEIN, HUMAN; LIGAND; MHC CLASS I-RELATED CHAIN A; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER CELL LINE; CD8+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I RELATED A GENE; MALE; METHYLATION; NATURAL KILLER GROUP 2 MEMBER D LIGAND GENE; NATURAL KILLER T CELL; PRIORITY JOURNAL; UL 16 BINDING PROTEIN 1 GENE; UL 16 BINDING PROTEIN 2 GENE; ACUTE MYELOBLASTIC LEUKEMIA; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE; TUMOR ESCAPE;

CELL LINE, TUMOR; DNA METHYLATION; GPI-LINKED PROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIGANDS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; TUMOR ESCAPE;

EID: 84921614969     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2014.58     Document Type: Article

References (59)

1. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell 2010; 142: 847-856.
2. Lopez-Larrea C, Suarez-Alvarez B, Lopez-Soto A, Lopez-Vazquez A, Gonzalez S. The NKG2D receptor: sensing stressed cells. Trends Mol Med 2008; 14: 179-189.
3. Gonzalez S, Lopez-Soto A, Suarez-Alvarez B, Lopez-Vazquez A, Lopez-Larrea C. NKG2D ligands: key targets of the immune response. Trends Immunol 2008; 29: 397-403.
4. Eagle RA, Traherne JA, Hair JR, Jafferji I, Trowsdale J. ULBP6/RAET1L is an additional human NKG2D ligand. Eur J Immunol 2009; 39: 3207-3216.
5. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186-1190.
6. Terme M, Borg C, Guilhot F, Masurier C, Flament C, Wagner EF et al. BCR/ABL promotes dendritic cell-mediated natural killer cell activation. Cancer Res 2005; 65: 6409-6417.
7. Unni AM, Bondar T, Medzhitov R. Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc Natl Acad Sci USA 2008; 105: 1686-1691.
8. Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res 2011; 71: 5998-6009.
9. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-738.
10. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 2006; 55: 1584-1589.
11. Song H, Kim J, Cosman D, Choi I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol 2006; 239: 22-30.
12. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66: 2520-2526.
13. Liu G, Atteridge CL, Wang X, Lundgren AD, Wu JD. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chainrelated molecule A independent of A disintegrin and metalloproteinases. J Immunol 2010; 184: 3346-3350.
14. Sun D, Wang X, Zhang H, Deng L, Zhang Y. MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int 2011; 35: 569-574.
15. Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Furst D et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the 'a disintegrin and metalloproteases' 10 and 17. Int J Cancer 2013; 133: 1557-1566.
16. Duan X, Mao X, Sun W. ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells. Mol Med Rep 2013; 7: 991-997.
17. Fernandez-Messina L, Ashiru O, Boutet P, Aguera-Gonzalez S, Skepper JN, Reyburn HT et al. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem 2010; 285: 8543-8551.
18. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH et al. Disulphideisomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 2007; 447: 482-486.
19. Huergo-Zapico L, Gonzalez-Rodriguez AP, Contesti J, Gonzalez E, Lopez-Soto A, Fernandez-Guizan A et al. Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding. Cancer Immunol Immunother 2012; 61: 1201-1210.
20. Aguera-Gonzalez S, Gross CC, Fernandez-Messina L, Ashiru O, Esteso G, Hang HC et al. Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding. Eur J Immunol 2011; 41: 3667-3676.
21. Baraganõ Raneros A, Suarez-Álvarez B, López-Larrea C. Secretory pathways generating immunosuppressive NKG2D ligands: new targets for therapeutic intervention. Oncoimmunology 2014; 3: e28497.
22. Stone R, Sekeres M, Garcia-Manero G. Evolving strategies in the treatment of MDS and AML. Clin Adv Hematol Oncol 2009; 7: 1-14 quiz 12 p following 14.
23. Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipowicz A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cellmediated lysis. Leuk Res 2007; 31: 1393-1402.
24. Schmiedel BJ, Arelin V, Gruenebach F, Krusch M, Schmidt SM, Salih HR. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer 2011; 128: 2911-2922.
25. Tang KF, He CX, Zeng GL, Wu J, Song GB, Shi YS et al. Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine. Biochem Biophys Res Commun 2008; 370: 578-583.
26. Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M et al. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 2007; 21: 2103-2108.
27. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008; 111: 1428-1436.
28. Lopez-Soto A, Folgueras AR, Seto E, Gonzalez S. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene 2009; 28: 2370-2382.
29. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 2009; 23: 641-648.
30. Lu X, Ohata K, Kondo Y, Espinoza JL, Qi Z, Nakao S. Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cellmediated cytolysis. Cancer Sci 2010; 101: 609-615.
31. Huang B, Sikorski R, Sampath P, Thorne SH. Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J Immunother 2011; 34: 289-296.
32. Yang F, Shao Y, Liu M, Huang J, Zhu K, Guo C et al. Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity. Arch Med Sci 2013; 9: 323-331.
33. Wu X, Tao Y, Hou J, Meng X, Shi J. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Neoplasia 2012; 14: 1178-1189.
34. Berghuis D, Schilham MW, Vos HI, Santos SJ, Kloess S, Buddingh EP et al. Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin Sarcoma Res 2012; 2: 8.
35. Sers C, Kuner R, Falk CS, Lund P, Sueltmann H, Braun M et al. Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. Int J Cancer 2009; 125: 1626-1639.
36. Schrambach S, Ardizzone M, Leymarie V, Sibilia J, Bahram S. In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. PLoS ONE 2007; 2: e518.
37. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123-133.
38. Fernandez-Messina L, Reyburn HT, Vales-Gomez M. Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front Immunol 2012; 3: 299.
39. Stern-Ginossar N, Mandelboim O. An integrated view of the regulation of NKG2D ligands. Immunology 2009; 128: 1-6.
40. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005; 105: 3615-3622.
41. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005; 105: 2066-2073.
42. Sanchez-Correa B, Morgado S, Gayoso I, Bergua JM, Casado JG, Arcos MJ et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother 2011; 60: 1195-1205.
43. Hilpert J, Grosse-Hoves L, Grunebach F, Buechele C, Nuebling T, Raum T et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012; 189: 1360-1371.
44. Kamimura H, Yamagiwa S, Tsuchiya A, Takamura M, Matsuda Y, Ohkoshi S et al. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. J Hepatol 2012; 56: 381-388.
45. de Kruijf EM, Sajet A, van Nes JG, Putter H, Smit VT, Eagle RA et al. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer 2012; 12: 24.
46. Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007; 8: 286-298.
47. McGilvray RW, Eagle RA, Watson NF, Al-Attar A, Ball G, Jafferji I et al. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 2009; 15: 6993-7002.
48. Calvanese V, Fernandez AF, Urdinguio RG, Suarez-Alvarez B, Mangas C, Perez-Garcia V et al. A promoter DNA demethylation landscape of human hematopoietic differentiation. Nucleic Acids Res 2012; 40: 116-13147.
49. Bormann F, Sers C, Seliger B, Handke D, Bergmann T, Seibt S et al. Methylation-specific ligation detection reaction (msLDR): a new approach for multiplex evaluation of methylation patterns. Mol Genet Genomics 2011; 286: 279-291.
50. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.
51. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670-2677.
52. Schmiedel BJ, Arélin V, Gruenebach F, Krush M, Schmidt SM, Salih HR. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer 2011; 128: 2911-2922.
53. Koch J, Steinle A, Watzl C, Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 2013; 34: 182-191.
54. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99: 3661-3667.
55. Verheyden S, Bernier M, Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 2004; 18: 2002-2007.
56. Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R et al. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol 2012; 90: 109-115.
57. Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 2014; 99: 836-847.
58. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.
59. Locatelli F, Pende D, Maccario R, Mingari MC, Moretta A, Moretta L. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. Clin Immunol 2009; 133: 171-178.